Approval Triggers Milestone Payment of $7.5 Million from Sanofi; Cytokinetics Eligible to Receive Additional Milestone Payments and Royalties on ...

The AHA is expanding its initiative to improve detection, standardize care, and enhance treatment for hypertrophic cardiomyopathy.

Alnylam Canada ULC is pleased to announce that Health Canada has issued a Notice of Compliance (NOC) authorizing AMVUTTRA® (vutrisiran) for the treatment of cardiomyopathy in adult patients with ...

Six months after receiving a surprise rejection due to what the FDA called “lack of substantial evidence of effectiveness,” Capricor’s cell therapy deramiocel showed significant benefits in upper-limb ...

Final Decision from European Commission Expected in Q1 2026SOUTH SAN FRANCISCO, Calif., (GLOBE NEWSWIRE) -- Cytokinetics, ...

The diagnosis of a potentially lethal cardiovascular disease in a young athlete presents a complex dilemma regarding athlete safety, patient autonomy, team or institutional risk tolerance and medical ...

A genetic variant is likely putting some children suffering with myocarditis—inflammation of the heart muscle—at higher risk ...

Feline HCM remains a complex, prevalent, and often-devastating disease. While cats can remain asymptomatic for years, progression to CHF or thromboembolism can be sudden. A structured approach to ...

HELIOS-B is a global, randomized, double-blind, placebo-controlled clinical trial that evaluated the efficacy and safety of AMVUTTRA (R) in adult patients with wtATTR or hATTR amyloidosis with ...

The findings of a study strongly suggest that genetic testing should be done on all children with heart failure and ...